Navigation Links
Downgraded Tier Positions and Step Therapy Restrictions Have Stalled Exforge's and Tekturna's Growth in The Hypertension Drug Market

MCO Pharmacy Directors Favor Individual, Generic Drugs Versus Newer Single-Pill Fixed Combination Brands, According to a New Report from HealthLeaders-InterStudy

NASHVILLE, Tenn., Dec. 10 /PRNewswire/ -- HealthLeaders-InterStudy, a leading provider of managed care market intelligence, finds that although Novartis' Exforge and Tekturna have slowly penetrated tier 2 levels of managed care organization (MCO) formularies over the last 12 months, their progress has stalled. Tekturna has stumbled from having 5.1 percent of U.S. patients accessing the drug at tier 2 in August 2008 to having only 3.9 percent of all patients with access at that same level in November 2008. According to the new Formulary Forum report entitled Formulary Advantages in Hypertension: Penetration of Advantaged Tiers by Novel Agents and Fixed-Dose Combinations, more surveyed MCO pharmacy directors indicate that they have downgraded Exforge's and Tekturna's tier position and/or added step therapy restrictions than indicated they had improved tier positioning of the drugs.

"The future reimbursement outlook for repackaging of individual hypertension agents is not that promising," according to Jason Labonte, Ph.D., vice president at HealthLeaders-InterStudy. "Forty-four to 67 percent of survey respondents favor use of individual (and often generic) drugs versus the newer single-pill, fixed-combination brands like Exforge and Daiichi Sankyo's Azor."

About Formulary Advantages in Hypertension: Penetration of Advantaged Tiers by Novel Agents and Fixed-Dose Combinations

The new Formulary Forum report is based on a survey of 50 pharmacy directors who control national, regional and state-level MCOs. Answers were segmented by type of plan to illustrate variances in strategy by size of plan. The easy-to-use PowerPoint format allows users to cut-and-paste graphs and data into their own presentations.

About Formulary Forum

Formulary Forum is the first and only source for identifying the trends in formulary positioning of competing agents, understanding why those trends were taking place and predicting what changes lay ahead for brand positioning in the face of both patent expiries and new drug launches. The new report series from HealthLeaders-InterStudy combines historical formulary data from Fingertip Formulary, which maintains the highest quality and most comprehensive, integrated database of formulary information in the United States, with a robust survey of 50 MCO pharmacy directors. The pharmacy directors responses reveal what events triggered movement of key brands within their formulary for a specific disease as well as what moves they expect to make in formulary structure as new brands enter the market.

About Fingertip Formulary

Fingertip Formulary ( offers comprehensive formulary data covering commercial, Medicaid, Medicare and PBM plans, among others, in the United States. Fingertip Formulary is a Decision Resources, Inc. company.

About HealthLeaders-InterStudy

HealthLeaders-InterStudy, a Decision Resources, Inc. company, is the authoritative source for managed care data, analysis and news. For more information, please visit

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Both HealthLeaders-InterStudy and Fingertip Formulary are Decision Resources, Inc. companies. Please visit Decision Resources, Inc. at

All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.

    For more information, contact:

    Lisa Osgood                                 Elizabeth Marshall
    HealthLeaders-InterStudy                    Decision Resources, Inc.
    781-296-2606                                781-296-2563                

SOURCE HealthLeaders-InterStudy
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. 11.4% Shareholders & Former Executive Management of LCA-Vision Seek Board Representation and Executive Management Positions
2. More Than 1,600 Positions to be Filled at PharmaDiversity Job Board's eJobFair in September
3. Siemens Healthcare Executives Recognized With New Industry Leadership Positions
4. Essilor Strengthens its Positions in Italy - Three New Acquisitions in the United States
5. Debate Will Feature Clinton-Obama Positions on Health Care Followed by Straw Poll
6. New therapy prevents dangerous side effect for lymphoma patients
7. Intense chemotherapy wards off recurrence in half of mantle cell lymphoma patients after seven years
8. Statin Use Doesnt Inhibit Lymphoma Drug Therapy
9. Three Italian Multicenter Studies Report High (>70%) Rates of Complete Remission (CR) Utilizing Zevalin Radio-Immunotherapy (RIT) in Treatment of Newly Diagnosed or Relapsed or Refractory Non-Hodgkins Lymphoma
10. 33rd Annual Hutch Holiday Gala Raises Millions for Cancer Immunotherapy Research
11. Lenalidomide safe as single therapy for elderly CLL patients
Post Your Comments:
(Date:11/27/2015)... ... , ... ProSidebar: Fashion is a set of 30 kinetic edge ... video editors can easily add an informative sidebar to any FCPX production. Create ... featuring self-animating drop zones, lines, bars, and text with the ease of FCPX's drag ...
(Date:11/27/2015)... ... November 27, 2015 , ... Intellitec Solutions announced today ... Group (MSDSLUG). Recognized as Microsoft’s official group for end users of Dynamics SL ... users, partners, industry experts and representatives. Intellitec Solutions’ membership status demonstrates their ongoing ...
(Date:11/27/2015)... ... November 27, 2015 , ... Keeping in mind challenges ... health and wellness consultation, has collaborated with a leading web-based marketplace for extra-curricular ... experienced by parents and bring advice from parenting experts within their reach. As ...
(Date:11/27/2015)... ... November 27, 2015 , ... Dr. Thomas Dunlap and Dr. ... Tucker Bierbaum with Emergency Medicine at St., Joseph Health System’s Santa Rosa Memorial ... conditions present in similar ways and require time-critical intervention to avoid large area heart ...
(Date:11/26/2015)... ... 26, 2015 , ... Patients at Serenity Point Recovery, a ... on Thanksgiving Day to share the things that they are most grateful for ... YouTube channel, patients displayed what they wrote on index cards, describing the things ...
Breaking Medicine News(10 mins):
(Date:11/25/2015)... Nov. 25, 2015 On Tuesday, November ... bellwether trial against Wright Medical Technology, Inc. for ... Conserve metal-on-metal hip implant device, awarded $11 million ... two week trial and three days of deliberations, ... device was defectively designed and unreasonably dangerous, and ...
(Date:11/25/2015)... Nov. 25, 2015  Henry Schein, Inc., the world,s ... office-based dental, medical and animal health practitioners, will unveil ... Henry Schein ConnectDental® Pavilion , which brings together ... open solutions designed to help any practice or laboratory ... for a schedule of experts appearing at the ...
(Date:11/25/2015)... plc (NYSE: AGN ) today announced that it has ... Attorney General,s Office to end the litigation under ... the Attorney General over the decision of Forest Laboratories, Inc., ... now generic version of memantine immediate release tablets.  Under the ... counterclaims against New York , and has ...
Breaking Medicine Technology: